MY209059A - Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone - Google Patents

Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone

Info

Publication number
MY209059A
MY209059A MYPI2022001012A MYPI2022001012A MY209059A MY 209059 A MY209059 A MY 209059A MY PI2022001012 A MYPI2022001012 A MY PI2022001012A MY PI2022001012 A MYPI2022001012 A MY PI2022001012A MY 209059 A MY209059 A MY 209059A
Authority
MY
Malaysia
Prior art keywords
ophthalmic composition
aqueous ophthalmic
polyvinylpyrrolidone
diquafosol
salt
Prior art date
Application number
MYPI2022001012A
Other languages
English (en)
Inventor
Kamimura Asuka
Momokawa Yusuke
Endo Kenichi
Morishima Kenji
Asada Hiroyuki
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MY209059A publication Critical patent/MY209059A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI2022001012A 2019-08-27 2020-08-25 Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone MY209059A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019154525 2019-08-27
PCT/JP2020/031917 WO2021039748A1 (ja) 2019-08-27 2020-08-25 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物

Publications (1)

Publication Number Publication Date
MY209059A true MY209059A (en) 2025-06-18

Family

ID=74685901

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022001012A MY209059A (en) 2019-08-27 2020-08-25 Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone

Country Status (7)

Country Link
JP (3) JP6966667B2 (https=)
KR (2) KR102656181B1 (https=)
CN (2) CN114286670B (https=)
MY (1) MY209059A (https=)
PH (1) PH12022550474A1 (https=)
TW (1) TWI848171B (https=)
WO (1) WO2021039748A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117137866A (zh) * 2018-02-28 2023-12-01 参天制药株式会社 含有地夸磷索及阳离子性聚合物的眼科用组合物
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
CA3215750A1 (en) * 2021-03-30 2022-10-06 Senju Pharmaceutical Co., Ltd. Suspension containing heterocyclidene acetamide derivative
CN114646705A (zh) * 2022-03-22 2022-06-21 武汉绿合医药科技有限公司 一种地夸磷索钠滴眼液有关物质含量检测方法
JP7245383B1 (ja) 2022-09-20 2023-03-23 参天製薬株式会社 ジクアホソルまたはその塩を含有する眼科用組成物のｐＨの低下を抑制する方法
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0365270A (ja) 1989-07-31 1991-03-20 Kanzaki Paper Mfg Co Ltd 塗布シートの製造方法
JPH0365270U (https=) 1989-10-31 1991-06-25
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
KR100549904B1 (ko) * 1996-03-27 2006-05-16 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 우리딘트리포스페이트및관련화합물을함유하는섬모운동장해치료용약학조성물
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
AU2225701A (en) * 1999-12-27 2001-07-09 Santen Pharmaceutical Co. Ltd. System for stabilizing lacrimal fluid layer
AU2001260643B9 (en) * 2000-05-30 2006-10-19 Merck Sharp & Dohme Corp. Ectocornea extension promoters
KR20070114130A (ko) * 2005-02-14 2007-11-29 존슨 앤드 존슨 비젼 케어, 인코포레이티드 착용감이 편안한 안용 장치 및 이의 제조방법
CN106729718A (zh) * 2010-09-10 2017-05-31 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
UA113839C2 (xx) * 2010-12-28 2017-03-27 Очний розчин, який містить диквафозол, спосіб його отримання і спосіб інгібування утворення нерозчинного осаду
KR20120077080A (ko) 2010-12-30 2012-07-10 동우 화인켐 주식회사 광학필름 및 이를 이용한 백라이트 유닛
US20160213708A1 (en) * 2012-01-08 2016-07-28 Medicure Technologies Ltd. Ophthalmic composition
KR101536885B1 (ko) * 2012-03-26 2015-07-14 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 함유 점안액
JP2015032653A (ja) 2013-08-01 2015-02-16 株式会社東芝 固体撮像装置
JP6267003B2 (ja) 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
EP3139903B1 (en) * 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
KR102330736B1 (ko) * 2014-12-25 2021-11-23 산텐 세이야꾸 가부시키가이샤 수성 점안액
CN107635565A (zh) * 2015-06-05 2018-01-26 参天制药株式会社 以向佩戴有软性隐形眼镜的干眼症患者的眼中滴入的方式使用为特征的干眼症治疗剂
CN107837276A (zh) * 2016-09-19 2018-03-27 刘力 局部给药的药物组合物
CN117137866A (zh) * 2018-02-28 2023-12-01 参天制药株式会社 含有地夸磷索及阳离子性聚合物的眼科用组合物
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物

Also Published As

Publication number Publication date
CN114286670B (zh) 2024-01-16
JP2025031918A (ja) 2025-03-07
CN117771172A (zh) 2024-03-29
JP2022003099A (ja) 2022-01-11
CN114286670A (zh) 2022-04-05
TWI848171B (zh) 2024-07-11
KR20220052971A (ko) 2022-04-28
JP7614069B2 (ja) 2025-01-15
JPWO2021039748A1 (ja) 2021-09-30
TW202122094A (zh) 2021-06-16
PH12022550474A1 (en) 2023-03-06
KR102656181B1 (ko) 2024-04-08
KR20240049646A (ko) 2024-04-16
JP6966667B2 (ja) 2021-11-17
WO2021039748A1 (ja) 2021-03-04

Similar Documents

Publication Publication Date Title
MY209059A (en) Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
CL2018000033A1 (es) Composición para destapar una nariz tapada que tiene actividad antiviral.
MY200975A (en) "Compositions Comprising Amino acids for use in the Treatment of Mitochondrial Dysfunction-Related Diseases"
WO2016007629A3 (en) Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations
MY192577A (en) Ophthalmic solution comprising epinastine
AU2017356887A8 (en) sGC stimulators
EP3575314A3 (en) Glucagon derivatives
JP2017002035A5 (https=)
AR105199A1 (es) Soluciones oftálmicas acuosas
JP2017502074A5 (https=)
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
HRP20180468T1 (hr) Novi derivat analoga inzulina
MX2017016418A (es) Composiciones de liraglutida de acción prolongada.
WO2016177908A3 (fr) Procede de traitement des matieres keratiniques a partir de derives de c-glycosides amides, acides ou ester, et la composition cosmetique les contenant
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
NZ602126A (en) Ophthalmic Solution for Treating Ocular Infection Comprising Levofloxacin or Salt Thereof or Solvate of the Same, Method for Treating Ocular Infection, Levofloxacin or Salt Thereof or Solvate of the Same, and Use Thereof
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
WO2018230858A3 (ko) Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
BR112019004838A2 (pt) tratamento de linfoma não-hodgkin usando lilotomab e 177lu-lilotomab satetraxetan
PL430029A1 (pl) Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu
SA518391400B1 (ar) تركيب للمعالجة من العقم في كائن أنثوي
MX369075B (es) Composicion para el cuidado de la piel y uso de la misma.
EA201591994A1 (ru) Цистеин или его производное для лечения атрофического гастрита